Appeal No. 96-0965
Application 08/054,548
may be administered simultaneously or sequentially (page 6, second paragraph;
paragraph bridging pages 6 and 7). In the specification, Appellants teach the optimum
molar ratios of the compounds recited in claim 8 (page 7, second full paragraph).
Appellants also describe suitable dose ranges of the claimed combination (paragraph
bridging pages 7 and 8); suitable modes of administration (page 7, lines 3 through 7; page
8, first full paragraph); and suitable pharmaceutical formulations (page 8, first full
paragraph through page 10, fourth paragraph). In the specification, paragraph bridging
pages 10 and 11, Appellants teach the preparation of zidovudine. Appellants also
describe alternative methods for preparing the other compound recited in claim 8 (pages
11 through 14). Further, Appellants provide detailed information respecting tablet
formulations, capsule formulations, injectable formulations, and intramuscular injection
formulation, a syrup, a suppository, and pessaries (pages 16 through 22). Example 8 in
the specification (page 23) is a working example describing the preparation of 1-(2-
(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine. Finally, Appellants set forth a
working example describing the in vitro synergistic effect of the compounds recited in
claim 8. (pages 24 and 25).
All in all, we believe that the specification imparts ample information to persons
6
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007